PFE Stock Recent News

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

A Wall Street maxim states, “Twenty percent of investors who want to make money are in stocks, while the other 80 percent who want to keep their money are in bonds.

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Key Points Focus on low-priced, low-beta stocks to populate your $5,000 portfolio. Add in a few low-cost, risk-reduced ETFs for enhanced diversification. Are you ahead, or behind on retirement? SmartAsset’s free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don’t waste another minute; get started by clicking here.(Sponsor) Investing in the 2020s isn’t exclusively for the wealthy. With as little as $5,000, you can build a low-cost portfolio with excellent growth potential for the long term. Selecting a handful of affordable stocks and low-priced exchange traded funds (ETFs) will allow you to diversify and thereby de-risk your portfolio. As we’ll see, a few simple strategies can help you turn your $5,000 into a worry-free passive income generator. Finding Affordable, Low-Risk Stocks To properly diversify your $5,000 portfolio, you’ll want to select so

I analyze the 50 Fortune World's Most Admired Companies, focusing on dividend-paying stocks and their yield-based investment potential. Three companies—Pfizer, BMW, and Singapore Airlines—currently meet my 'IDEAL' dividend criteria, with dividends from $1K invested exceeding their single share prices. They, however, are not 'safer.' Analyst estimates project 12.88% to 37.22% net gains for the top ten dividend-yielding Fortune WMA stocks by July 2026, with moderate risk.

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a long-running legal dispute between the two sides.

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochem.

JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.

Pfizer (PFE) closed at $25.62 in the latest trading session, marking a +1.51% move from the prior day.

Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.